Basking Ridge, NJNCT07872553Now EnrollingIRB Ready

Renal Cell Carcinoma Clinical Trial in Basking Ridge, NJ

Access cutting-edge renal cell carcinoma treatment through this early phase 1 clinical trial at a research site in Basking Ridge. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Basking Ridge location

Preparing your pre-screening questions…

Expert Care in Basking Ridge

Access renal cell carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related renal cell carcinoma treatment provided free

Apply for This Basking Ridge Location

Check if you qualify for this renal cell carcinoma clinical trial in Basking Ridge, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Basking Ridge

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Basking Ridge site if eligible
  4. 4Begin participation

About This Renal Cell Carcinoma Study in Basking Ridge

The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Patients: A patient cannot be considered eligible for this study unless ALL of the following conditions are met.
Patient is receiving standard of care treatment for renal cell carcinoma for one of the following indications: 1) NIVO monotherapy as maintenance, after ipilimumab and NIVO induction (up to 4 doses), 2) NIVO monotherapy as single-agent treatment, OR 3) adjuvant PEMBRO monotherapy or combination therapy with belzutifan. Of note, patient does not need to be newly initiating treatment to be eligible for this study.
For patients on NIVO monotherapy or PEMBRO (Groups 2 and 3 above), they must have received at least 1 dose as a standard of care to be eligible
Patient has at least 6 doses of planned treatment left as standard of care that can be given on protocol (either NIVO or PEMBRO)
For example, standard of care for adjuvant PEMBRO is 1 year of therapy which can be given at 3 (17 doses) or 6 (9 doses) week intervals. Patients can enter this trial after starting treatment but must have at least 6 doses of treatment left to be eligible.
For example, standard of care for maintenance NIVO (after ipilimumab + NIVO) is typically about 2 years of therapy. NIVO can be given at 2 (about 52 doses) or 4 week (about 26 doses) intervals.
Ability to speak and read English because we do not have the resources to translate all materials into other languages
Patient must be able to provide written informed consent, or a legal authorized representative (LAR)/caregiver must be identified to provide consent in cases where the patient cannot.
Patients are unable to receive investigational agents on other clinical trial protocols Providers (Medical Oncologists):
Medical oncologists in the genitourinary medical oncology department will be involved with this study if they are the treating investigator for patients who consent to this study
The medical oncologists who are involved in this will be asked to complete surveys

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Basking Ridge?

Yes, this clinical trial (NCT07872553) has an active research site in Basking Ridge, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Renal Cell Carcinoma Treatment Options in Basking Ridge, NJ

If you're searching for renal cell carcinoma treatment options in Basking Ridge, NJ, this clinical trial (NCT07872553) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Basking Ridge research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced renal cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all renal cell carcinoma clinical trials near you to find additional studies recruiting in your area.

More Kidney Cancer Trials in Basking Ridge, NJ

See all kidney cancer clinical trials recruiting in Basking Ridge — not just this study.

Browse Kidney Cancer Trials in Basking Ridge →

Browse More Trials by Condition

Kidney Cancer TrialsAll Conditions →

Ready to Join in Basking Ridge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Basking Ridge, NJ